nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Everolimus—kidney cancer	0.135	0.293	CbGbCtD
Maraviroc—CYP3A4—Temsirolimus—kidney cancer	0.0912	0.198	CbGbCtD
Maraviroc—CYP3A4—Pazopanib—kidney cancer	0.0479	0.104	CbGbCtD
Maraviroc—CYP3A4—Erlotinib—kidney cancer	0.0342	0.0741	CbGbCtD
Maraviroc—CYP3A4—Paclitaxel—kidney cancer	0.0313	0.0678	CbGbCtD
Maraviroc—CYP3A4—Sorafenib—kidney cancer	0.0278	0.0603	CbGbCtD
Maraviroc—CYP3A4—Vinblastine—kidney cancer	0.0274	0.0595	CbGbCtD
Maraviroc—CYP3A4—Vincristine—kidney cancer	0.027	0.0585	CbGbCtD
Maraviroc—CYP3A4—Sunitinib—kidney cancer	0.0225	0.0488	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—kidney cancer	0.0169	0.0366	CbGbCtD
Maraviroc—CCR5—Binding and entry of HIV virion—CD4—kidney cancer	0.0108	0.125	CbGpPWpGaD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—CD4—kidney cancer	0.00395	0.0458	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CARD11—kidney cancer	0.00291	0.0337	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—TCEB1—kidney cancer	0.00264	0.0307	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—TCEB2—kidney cancer	0.00264	0.0307	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD8A—kidney cancer	0.00215	0.0249	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—PAK1—kidney cancer	0.00203	0.0236	CbGpPWpGaD
Maraviroc—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00198	0.023	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—TCEB2—kidney cancer	0.00183	0.0212	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—TCEB1—kidney cancer	0.00183	0.0212	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD8A—kidney cancer	0.00155	0.018	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—RELA—kidney cancer	0.00126	0.0146	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.00125	0.0145	CbGpPWpGaD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.00125	0.0144	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—MTOR—kidney cancer	0.00124	0.0143	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD4—kidney cancer	0.00123	0.0143	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—OR4C13—kidney cancer	0.00122	0.0141	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—kidney cancer	0.00114	0.0132	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—PSMD7—kidney cancer	0.00112	0.013	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—OR4C13—kidney cancer	0.0011	0.0128	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—ANXA1—kidney cancer	0.00105	0.0122	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—RAF1—kidney cancer	0.000915	0.0106	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—RELA—kidney cancer	0.000911	0.0106	CbGpPWpGaD
Maraviroc—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000903	0.0105	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD4—kidney cancer	0.000892	0.0103	CbGpPWpGaD
Maraviroc—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000836	0.0097	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000836	0.0097	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—JUN—kidney cancer	0.000798	0.00926	CbGpPWpGaD
Maraviroc—CCR5—Disease—CCBL1—kidney cancer	0.000745	0.00864	CbGpPWpGaD
Maraviroc—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000709	0.00823	CbGpPWpGaD
Maraviroc—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.0007	0.00812	CbGpPWpGaD
Maraviroc—CCR5—Disease—AMER1—kidney cancer	0.000673	0.00781	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK3—kidney cancer	0.00066	0.00765	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—OR4C13—kidney cancer	0.000652	0.00757	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—CD4—kidney cancer	0.000641	0.00744	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—ANXA1—kidney cancer	0.000637	0.00739	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK1—kidney cancer	0.000628	0.00728	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—POMC—kidney cancer	0.000611	0.00708	CbGpPWpGaD
Maraviroc—CCR5—Disease—GPC3—kidney cancer	0.000564	0.00655	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LATS1—kidney cancer	0.000555	0.00643	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000535	0.00621	CbGpPWpGaD
Maraviroc—CCR5—Disease—ST3GAL2—kidney cancer	0.000522	0.00606	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—POMC—kidney cancer	0.000515	0.00598	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKAP13—kidney cancer	0.000505	0.00586	CbGpPWpGaD
Maraviroc—CCR5—Disease—PGK1—kidney cancer	0.000489	0.00568	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC5A3—kidney cancer	0.000489	0.00568	CbGpPWpGaD
Maraviroc—CCR5—Disease—LDHB—kidney cancer	0.00048	0.00557	CbGpPWpGaD
Maraviroc—CCR5—Disease—SFRP2—kidney cancer	0.00048	0.00557	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AMER1—kidney cancer	0.000472	0.00547	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKAP13—kidney cancer	0.000458	0.00532	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000457	0.00531	CbGpPWpGaD
Maraviroc—CCR5—Disease—TCEB1—kidney cancer	0.000447	0.00519	CbGpPWpGaD
Maraviroc—CCR5—Disease—TCEB2—kidney cancer	0.000447	0.00519	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CD4—kidney cancer	0.000443	0.00514	CbGpPWpGaD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000442	0.00513	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—ITPR2—kidney cancer	0.000429	0.00498	CbGpPWpGaD
Maraviroc—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000424	0.00492	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.00041	0.00475	CbGpPWpGaD
Maraviroc—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000402	0.00467	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GPC3—kidney cancer	0.000395	0.00458	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CER1—kidney cancer	0.000395	0.00458	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ITPR2—kidney cancer	0.00039	0.00452	CbGpPWpGaD
Maraviroc—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000385	0.00447	CbGpPWpGaD
Maraviroc—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.00037	0.00429	CbGpPWpGaD
Maraviroc—CCR5—Disease—RPL14—kidney cancer	0.000364	0.00422	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—ANXA1—kidney cancer	0.00036	0.00417	CbGpPWpGaD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000355	0.00412	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000351	0.00407	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.00034	0.00394	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SFRP2—kidney cancer	0.000336	0.0039	CbGpPWpGaD
Maraviroc—CCR5—Disease—ITPR2—kidney cancer	0.000329	0.00382	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ANXA1—kidney cancer	0.000327	0.00379	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—POMC—kidney cancer	0.000312	0.00362	CbGpPWpGaD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000276	0.0032	CbGpPWpGaD
Maraviroc—CCR5—Disease—PSMD7—kidney cancer	0.000276	0.0032	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKAP13—kidney cancer	0.000271	0.00314	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP2—kidney cancer	0.000271	0.00314	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000263	0.00305	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC2A1—kidney cancer	0.000249	0.00289	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GRB7—kidney cancer	0.000248	0.00287	CbGpPWpGaD
Maraviroc—CCR5—Disease—JUNB—kidney cancer	0.000247	0.00287	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ITPR2—kidney cancer	0.00023	0.00267	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNA1—kidney cancer	0.000209	0.00242	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EIF4EBP1—kidney cancer	0.000208	0.00241	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HSPB1—kidney cancer	0.000208	0.00241	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN2B—kidney cancer	0.000201	0.00234	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000193	0.00224	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PSMD7—kidney cancer	0.000193	0.00224	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TSC1—kidney cancer	0.000193	0.00224	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ANXA1—kidney cancer	0.000193	0.00224	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.00019	0.0022	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FLT1—kidney cancer	0.000187	0.00217	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000186	0.00216	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—POMC—kidney cancer	0.000176	0.00204	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JUNB—kidney cancer	0.000173	0.00201	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PAK1—kidney cancer	0.000173	0.00201	CbGpPWpGaD
Maraviroc—Pharyngitis—Capecitabine—kidney cancer	0.000165	0.000364	CcSEcCtD
Maraviroc—Urinary tract disorder—Capecitabine—kidney cancer	0.000164	0.000362	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000164	0.000362	CcSEcCtD
Maraviroc—Hypersensitivity—Sorafenib—kidney cancer	0.000164	0.000362	CcSEcCtD
Maraviroc—Insomnia—Vincristine—kidney cancer	0.000164	0.000362	CcSEcCtD
Maraviroc—Anorexia—Gemcitabine—kidney cancer	0.000164	0.000361	CcSEcCtD
Maraviroc—Vomiting—Vinblastine—kidney cancer	0.000163	0.000361	CcSEcCtD
Maraviroc—Dizziness—Erlotinib—kidney cancer	0.000163	0.000361	CcSEcCtD
Maraviroc—Connective tissue disorder—Capecitabine—kidney cancer	0.000163	0.00036	CcSEcCtD
Maraviroc—Vomiting—Everolimus—kidney cancer	0.000163	0.00036	CcSEcCtD
Maraviroc—Anaemia—Paclitaxel—kidney cancer	0.000163	0.00036	CcSEcCtD
Maraviroc—Urethral disorder—Capecitabine—kidney cancer	0.000163	0.000359	CcSEcCtD
Maraviroc—Paraesthesia—Vincristine—kidney cancer	0.000162	0.000359	CcSEcCtD
Maraviroc—Rash—Everolimus—kidney cancer	0.000162	0.000357	CcSEcCtD
Maraviroc—Dermatitis—Everolimus—kidney cancer	0.000161	0.000356	CcSEcCtD
Maraviroc—Headache—Vinblastine—kidney cancer	0.000161	0.000356	CcSEcCtD
Maraviroc—CCR5—Disease—HIF1A—kidney cancer	0.000161	0.00187	CbGpPWpGaD
Maraviroc—CCR5—Disease—TSC2—kidney cancer	0.000161	0.00186	CbGpPWpGaD
Maraviroc—Purpura—Doxorubicin—kidney cancer	0.00016	0.000355	CcSEcCtD
Maraviroc—Headache—Everolimus—kidney cancer	0.00016	0.000354	CcSEcCtD
Maraviroc—Body temperature increased—Dactinomycin—kidney cancer	0.00016	0.000354	CcSEcCtD
Maraviroc—Abdominal pain—Dactinomycin—kidney cancer	0.00016	0.000354	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—POMC—kidney cancer	0.00016	0.00186	CbGpPWpGaD
Maraviroc—Asthenia—Sorafenib—kidney cancer	0.00016	0.000352	CcSEcCtD
Maraviroc—Syncope—Paclitaxel—kidney cancer	0.000158	0.000349	CcSEcCtD
Maraviroc—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000158	0.000349	CcSEcCtD
Maraviroc—Leukopenia—Paclitaxel—kidney cancer	0.000158	0.000348	CcSEcCtD
Maraviroc—Hypersensitivity—Sunitinib—kidney cancer	0.000158	0.000348	CcSEcCtD
Maraviroc—Decreased appetite—Vincristine—kidney cancer	0.000157	0.000347	CcSEcCtD
Maraviroc—Pruritus—Sorafenib—kidney cancer	0.000157	0.000347	CcSEcCtD
Maraviroc—Vomiting—Erlotinib—kidney cancer	0.000157	0.000347	CcSEcCtD
Maraviroc—Erythema multiforme—Capecitabine—kidney cancer	0.000157	0.000347	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000156	0.000345	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Vincristine—kidney cancer	0.000156	0.000345	CcSEcCtD
Maraviroc—Fatigue—Vincristine—kidney cancer	0.000156	0.000345	CcSEcCtD
Maraviroc—Rash—Erlotinib—kidney cancer	0.000156	0.000344	CcSEcCtD
Maraviroc—Dermatitis—Erlotinib—kidney cancer	0.000156	0.000344	CcSEcCtD
Maraviroc—Insomnia—Gemcitabine—kidney cancer	0.000155	0.000343	CcSEcCtD
Maraviroc—Eye disorder—Capecitabine—kidney cancer	0.000155	0.000343	CcSEcCtD
Maraviroc—Headache—Erlotinib—kidney cancer	0.000155	0.000342	CcSEcCtD
Maraviroc—Loss of consciousness—Paclitaxel—kidney cancer	0.000155	0.000342	CcSEcCtD
Maraviroc—Pain—Vincristine—kidney cancer	0.000155	0.000342	CcSEcCtD
Maraviroc—Constipation—Vincristine—kidney cancer	0.000155	0.000342	CcSEcCtD
Maraviroc—Paraesthesia—Gemcitabine—kidney cancer	0.000154	0.000341	CcSEcCtD
Maraviroc—Cardiac disorder—Capecitabine—kidney cancer	0.000154	0.00034	CcSEcCtD
Maraviroc—Cough—Paclitaxel—kidney cancer	0.000154	0.000339	CcSEcCtD
Maraviroc—Asthenia—Sunitinib—kidney cancer	0.000154	0.000339	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000153	0.00178	CbGpPWpGaD
Maraviroc—Nausea—Vinblastine—kidney cancer	0.000153	0.000337	CcSEcCtD
Maraviroc—Convulsion—Paclitaxel—kidney cancer	0.000153	0.000337	CcSEcCtD
Maraviroc—Nausea—Everolimus—kidney cancer	0.000152	0.000336	CcSEcCtD
Maraviroc—Diarrhoea—Sorafenib—kidney cancer	0.000152	0.000336	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000151	0.00176	CbGpPWpGaD
Maraviroc—Pruritus—Sunitinib—kidney cancer	0.000151	0.000334	CcSEcCtD
Maraviroc—Angiopathy—Capecitabine—kidney cancer	0.000151	0.000333	CcSEcCtD
Maraviroc—Myalgia—Paclitaxel—kidney cancer	0.00015	0.000331	CcSEcCtD
Maraviroc—Mediastinal disorder—Capecitabine—kidney cancer	0.00015	0.000331	CcSEcCtD
Maraviroc—Anxiety—Paclitaxel—kidney cancer	0.000149	0.00033	CcSEcCtD
Maraviroc—Decreased appetite—Gemcitabine—kidney cancer	0.000149	0.00033	CcSEcCtD
Maraviroc—Hypersensitivity—Dactinomycin—kidney cancer	0.000149	0.00033	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000149	0.000329	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000148	0.000327	CcSEcCtD
Maraviroc—Discomfort—Paclitaxel—kidney cancer	0.000148	0.000327	CcSEcCtD
Maraviroc—Fatigue—Gemcitabine—kidney cancer	0.000148	0.000327	CcSEcCtD
Maraviroc—Gastrointestinal pain—Vincristine—kidney cancer	0.000148	0.000327	CcSEcCtD
Maraviroc—Dizziness—Sorafenib—kidney cancer	0.000147	0.000325	CcSEcCtD
Maraviroc—Pain—Gemcitabine—kidney cancer	0.000147	0.000324	CcSEcCtD
Maraviroc—Constipation—Gemcitabine—kidney cancer	0.000147	0.000324	CcSEcCtD
Maraviroc—Nausea—Erlotinib—kidney cancer	0.000147	0.000324	CcSEcCtD
Maraviroc—Alopecia—Capecitabine—kidney cancer	0.000147	0.000324	CcSEcCtD
Maraviroc—Diarrhoea—Sunitinib—kidney cancer	0.000146	0.000323	CcSEcCtD
Maraviroc—Mental disorder—Capecitabine—kidney cancer	0.000145	0.000321	CcSEcCtD
Maraviroc—Asthenia—Dactinomycin—kidney cancer	0.000145	0.000321	CcSEcCtD
Maraviroc—Malnutrition—Capecitabine—kidney cancer	0.000145	0.000319	CcSEcCtD
Maraviroc—Erythema—Capecitabine—kidney cancer	0.000145	0.000319	CcSEcCtD
Maraviroc—Oedema—Paclitaxel—kidney cancer	0.000144	0.000317	CcSEcCtD
Maraviroc—Body temperature increased—Vincristine—kidney cancer	0.000143	0.000316	CcSEcCtD
Maraviroc—Abdominal pain—Vincristine—kidney cancer	0.000143	0.000316	CcSEcCtD
Maraviroc—Infection—Paclitaxel—kidney cancer	0.000143	0.000315	CcSEcCtD
Maraviroc—Flatulence—Capecitabine—kidney cancer	0.000142	0.000315	CcSEcCtD
Maraviroc—CCR5—Disease—KIT—kidney cancer	0.000142	0.00165	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—kidney cancer	0.000142	0.00165	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF2—kidney cancer	0.000142	0.00164	CbGpPWpGaD
Maraviroc—Dizziness—Sunitinib—kidney cancer	0.000141	0.000313	CcSEcCtD
Maraviroc—Shock—Paclitaxel—kidney cancer	0.000141	0.000312	CcSEcCtD
Maraviroc—Vomiting—Sorafenib—kidney cancer	0.000141	0.000312	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—kidney cancer	0.000141	0.000312	CcSEcCtD
Maraviroc—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000141	0.000312	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CDKN2B—kidney cancer	0.000141	0.00164	CbGpPWpGaD
Maraviroc—Nervous system disorder—Paclitaxel—kidney cancer	0.000141	0.000311	CcSEcCtD
Maraviroc—Rash—Sorafenib—kidney cancer	0.00014	0.00031	CcSEcCtD
Maraviroc—Dermatitis—Sorafenib—kidney cancer	0.00014	0.000309	CcSEcCtD
Maraviroc—Breast disorder—Doxorubicin—kidney cancer	0.00014	0.000309	CcSEcCtD
Maraviroc—Skin disorder—Paclitaxel—kidney cancer	0.00014	0.000308	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000139	0.000308	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000139	0.000308	CcSEcCtD
Maraviroc—Headache—Sorafenib—kidney cancer	0.000139	0.000308	CcSEcCtD
Maraviroc—Diarrhoea—Dactinomycin—kidney cancer	0.000139	0.000306	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—kidney cancer	0.000138	0.000306	CcSEcCtD
Maraviroc—Anorexia—Paclitaxel—kidney cancer	0.000137	0.000303	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1R—kidney cancer	0.000137	0.00159	CbGpPWpGaD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000136	0.000301	CcSEcCtD
Maraviroc—Vomiting—Sunitinib—kidney cancer	0.000136	0.0003	CcSEcCtD
Maraviroc—Body temperature increased—Gemcitabine—kidney cancer	0.000136	0.0003	CcSEcCtD
Maraviroc—Tremor—Capecitabine—kidney cancer	0.000135	0.000299	CcSEcCtD
Maraviroc—Rash—Sunitinib—kidney cancer	0.000135	0.000298	CcSEcCtD
Maraviroc—Dermatitis—Sunitinib—kidney cancer	0.000135	0.000298	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—kidney cancer	0.000135	0.000297	CcSEcCtD
Maraviroc—Headache—Sunitinib—kidney cancer	0.000134	0.000296	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—kidney cancer	0.000134	0.000295	CcSEcCtD
Maraviroc—Anaemia—Capecitabine—kidney cancer	0.000134	0.000295	CcSEcCtD
Maraviroc—CCR5—Disease—BRAF—kidney cancer	0.000133	0.00155	CbGpPWpGaD
Maraviroc—Hypersensitivity—Vincristine—kidney cancer	0.000133	0.000295	CcSEcCtD
Maraviroc—Eosinophilia—Doxorubicin—kidney cancer	0.000132	0.000292	CcSEcCtD
Maraviroc—Nausea—Sorafenib—kidney cancer	0.000132	0.000292	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—RAF1—kidney cancer	0.000132	0.00153	CbGpPWpGaD
Maraviroc—Pancreatitis—Doxorubicin—kidney cancer	0.000131	0.00029	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000131	0.000289	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—IL2—kidney cancer	0.00013	0.00151	CbGpPWpGaD
Maraviroc—Angina pectoris—Doxorubicin—kidney cancer	0.00013	0.000288	CcSEcCtD
Maraviroc—Insomnia—Paclitaxel—kidney cancer	0.00013	0.000287	CcSEcCtD
Maraviroc—Asthenia—Vincristine—kidney cancer	0.00013	0.000287	CcSEcCtD
Maraviroc—Syncope—Capecitabine—kidney cancer	0.00013	0.000286	CcSEcCtD
Maraviroc—Leukopenia—Capecitabine—kidney cancer	0.000129	0.000286	CcSEcCtD
Maraviroc—Paraesthesia—Paclitaxel—kidney cancer	0.000129	0.000285	CcSEcCtD
Maraviroc—Vomiting—Dactinomycin—kidney cancer	0.000129	0.000284	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—kidney cancer	0.000129	0.000284	CcSEcCtD
Maraviroc—Rash—Dactinomycin—kidney cancer	0.000128	0.000282	CcSEcCtD
Maraviroc—Nausea—Sunitinib—kidney cancer	0.000127	0.000281	CcSEcCtD
Maraviroc—Loss of consciousness—Capecitabine—kidney cancer	0.000127	0.000281	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—kidney cancer	0.000127	0.00028	CcSEcCtD
Maraviroc—Cough—Capecitabine—kidney cancer	0.000126	0.000279	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—kidney cancer	0.000125	0.000276	CcSEcCtD
Maraviroc—Decreased appetite—Paclitaxel—kidney cancer	0.000125	0.000276	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000124	0.00144	CbGpPWpGaD
Maraviroc—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000124	0.000274	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000124	0.000274	CcSEcCtD
Maraviroc—Fatigue—Paclitaxel—kidney cancer	0.000124	0.000274	CcSEcCtD
Maraviroc—Diarrhoea—Vincristine—kidney cancer	0.000124	0.000273	CcSEcCtD
Maraviroc—Asthenia—Gemcitabine—kidney cancer	0.000123	0.000272	CcSEcCtD
Maraviroc—Myalgia—Capecitabine—kidney cancer	0.000123	0.000272	CcSEcCtD
Maraviroc—Pain—Paclitaxel—kidney cancer	0.000123	0.000271	CcSEcCtD
Maraviroc—Constipation—Paclitaxel—kidney cancer	0.000123	0.000271	CcSEcCtD
Maraviroc—Anxiety—Capecitabine—kidney cancer	0.000123	0.000271	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000122	0.00027	CcSEcCtD
Maraviroc—Discomfort—Capecitabine—kidney cancer	0.000122	0.000269	CcSEcCtD
Maraviroc—Pruritus—Gemcitabine—kidney cancer	0.000121	0.000268	CcSEcCtD
Maraviroc—Nausea—Dactinomycin—kidney cancer	0.00012	0.000266	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—kidney cancer	0.00012	0.000265	CcSEcCtD
Maraviroc—Dizziness—Vincristine—kidney cancer	0.00012	0.000264	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—kidney cancer	0.000119	0.000263	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—kidney cancer	0.000119	0.000263	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—IL2—kidney cancer	0.000118	0.00137	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000118	0.000261	CcSEcCtD
Maraviroc—Oedema—Capecitabine—kidney cancer	0.000118	0.000261	CcSEcCtD
Maraviroc—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000118	0.00026	CcSEcCtD
Maraviroc—Diarrhoea—Gemcitabine—kidney cancer	0.000117	0.000259	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—kidney cancer	0.000117	0.000259	CcSEcCtD
Maraviroc—Infection—Capecitabine—kidney cancer	0.000117	0.000259	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000117	0.000258	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—kidney cancer	0.000116	0.000257	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—kidney cancer	0.000116	0.000257	CcSEcCtD
Maraviroc—Shock—Capecitabine—kidney cancer	0.000116	0.000256	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—kidney cancer	0.000116	0.000256	CcSEcCtD
Maraviroc—Nervous system disorder—Capecitabine—kidney cancer	0.000116	0.000256	CcSEcCtD
Maraviroc—Vomiting—Vincristine—kidney cancer	0.000115	0.000254	CcSEcCtD
Maraviroc—Skin disorder—Capecitabine—kidney cancer	0.000115	0.000253	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000114	0.00133	CbGpPWpGaD
Maraviroc—Rash—Vincristine—kidney cancer	0.000114	0.000252	CcSEcCtD
Maraviroc—Dermatitis—Vincristine—kidney cancer	0.000114	0.000252	CcSEcCtD
Maraviroc—Body temperature increased—Paclitaxel—kidney cancer	0.000114	0.000251	CcSEcCtD
Maraviroc—Abdominal pain—Paclitaxel—kidney cancer	0.000114	0.000251	CcSEcCtD
Maraviroc—Headache—Vincristine—kidney cancer	0.000113	0.00025	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HIF1A—kidney cancer	0.000113	0.00131	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000113	0.000249	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TSC2—kidney cancer	0.000112	0.0013	CbGpPWpGaD
Maraviroc—Anorexia—Capecitabine—kidney cancer	0.000112	0.000248	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—kidney cancer	0.000112	0.000247	CcSEcCtD
Maraviroc—CCR5—Disease—RAF1—kidney cancer	0.000111	0.00129	CbGpPWpGaD
Maraviroc—Agranulocytosis—Doxorubicin—kidney cancer	0.000111	0.000246	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—kidney cancer	0.00011	0.00128	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—kidney cancer	0.000109	0.00127	CbGpPWpGaD
Maraviroc—Vomiting—Gemcitabine—kidney cancer	0.000109	0.000241	CcSEcCtD
Maraviroc—CCR5—Disease—MTOR—kidney cancer	0.000109	0.00126	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD4—kidney cancer	0.000108	0.00126	CbGpPWpGaD
Maraviroc—Rash—Gemcitabine—kidney cancer	0.000108	0.000239	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—kidney cancer	0.000108	0.000239	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KDR—kidney cancer	0.000108	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—kidney cancer	0.000108	0.00125	CbGpPWpGaD
Maraviroc—Headache—Gemcitabine—kidney cancer	0.000108	0.000238	CcSEcCtD
Maraviroc—Nausea—Vincristine—kidney cancer	0.000107	0.000237	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000107	0.000237	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—kidney cancer	0.000107	0.000237	CcSEcCtD
Maraviroc—Insomnia—Capecitabine—kidney cancer	0.000107	0.000236	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—kidney cancer	0.000106	0.000235	CcSEcCtD
Maraviroc—Paraesthesia—Capecitabine—kidney cancer	0.000106	0.000234	CcSEcCtD
Maraviroc—Hypersensitivity—Paclitaxel—kidney cancer	0.000106	0.000234	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—kidney cancer	0.000106	0.000233	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—kidney cancer	0.000105	0.000232	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—kidney cancer	0.000105	0.000232	CcSEcCtD
Maraviroc—Asthenia—Paclitaxel—kidney cancer	0.000103	0.000228	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—PTGS1—kidney cancer	0.000103	0.00119	CbGpPWpGaD
Maraviroc—Decreased appetite—Capecitabine—kidney cancer	0.000103	0.000226	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1B—kidney cancer	0.000102	0.00118	CbGpPWpGaD
Maraviroc—Nausea—Gemcitabine—kidney cancer	0.000102	0.000225	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000102	0.000225	CcSEcCtD
Maraviroc—Fatigue—Capecitabine—kidney cancer	0.000102	0.000225	CcSEcCtD
Maraviroc—Pruritus—Paclitaxel—kidney cancer	0.000102	0.000225	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—kidney cancer	0.000101	0.000224	CcSEcCtD
Maraviroc—Constipation—Capecitabine—kidney cancer	0.000101	0.000223	CcSEcCtD
Maraviroc—Pain—Capecitabine—kidney cancer	0.000101	0.000223	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—kidney cancer	0.0001	0.000221	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APC—kidney cancer	9.93e-05	0.00115	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KIT—kidney cancer	9.93e-05	0.00115	CbGpPWpGaD
Maraviroc—Cardiac disorder—Doxorubicin—kidney cancer	9.93e-05	0.000219	CcSEcCtD
Maraviroc—Diarrhoea—Paclitaxel—kidney cancer	9.83e-05	0.000217	CcSEcCtD
Maraviroc—Angiopathy—Doxorubicin—kidney cancer	9.71e-05	0.000214	CcSEcCtD
Maraviroc—Gastrointestinal pain—Capecitabine—kidney cancer	9.64e-05	0.000213	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—kidney cancer	9.64e-05	0.000213	CcSEcCtD
Maraviroc—CCR5—Disease—CTNNB1—kidney cancer	9.64e-05	0.00112	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—kidney cancer	9.51e-05	0.0011	CbGpPWpGaD
Maraviroc—Dizziness—Paclitaxel—kidney cancer	9.5e-05	0.00021	CcSEcCtD
Maraviroc—Alopecia—Doxorubicin—kidney cancer	9.46e-05	0.000209	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—POMC—kidney cancer	9.45e-05	0.0011	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—kidney cancer	9.39e-05	0.00109	CbGpPWpGaD
Maraviroc—Mental disorder—Doxorubicin—kidney cancer	9.38e-05	0.000207	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—BRAF—kidney cancer	9.34e-05	0.00108	CbGpPWpGaD
Maraviroc—Abdominal pain—Capecitabine—kidney cancer	9.32e-05	0.000206	CcSEcCtD
Maraviroc—Body temperature increased—Capecitabine—kidney cancer	9.32e-05	0.000206	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—kidney cancer	9.32e-05	0.000206	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—kidney cancer	9.32e-05	0.000206	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.28e-05	0.00108	CbGpPWpGaD
Maraviroc—Flatulence—Doxorubicin—kidney cancer	9.18e-05	0.000203	CcSEcCtD
Maraviroc—Vomiting—Paclitaxel—kidney cancer	9.14e-05	0.000202	CcSEcCtD
Maraviroc—Rash—Paclitaxel—kidney cancer	9.06e-05	0.0002	CcSEcCtD
Maraviroc—Dermatitis—Paclitaxel—kidney cancer	9.05e-05	0.0002	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MAPK1—kidney cancer	9.05e-05	0.00105	CbGpPWpGaD
Maraviroc—Headache—Paclitaxel—kidney cancer	9e-05	0.000199	CcSEcCtD
Maraviroc—Hypersensitivity—Capecitabine—kidney cancer	8.69e-05	0.000192	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—kidney cancer	8.65e-05	0.001	CbGpPWpGaD
Maraviroc—Anaemia—Doxorubicin—kidney cancer	8.61e-05	0.00019	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KRAS—kidney cancer	8.55e-05	0.000992	CbGpPWpGaD
Maraviroc—Nausea—Paclitaxel—kidney cancer	8.54e-05	0.000189	CcSEcCtD
Maraviroc—Asthenia—Capecitabine—kidney cancer	8.46e-05	0.000187	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—kidney cancer	8.35e-05	0.000185	CcSEcCtD
Maraviroc—Pruritus—Capecitabine—kidney cancer	8.34e-05	0.000184	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—kidney cancer	8.34e-05	0.000184	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—kidney cancer	8.19e-05	0.000181	CcSEcCtD
Maraviroc—Cough—Doxorubicin—kidney cancer	8.13e-05	0.00018	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—kidney cancer	8.07e-05	0.000178	CcSEcCtD
Maraviroc—Diarrhoea—Capecitabine—kidney cancer	8.07e-05	0.000178	CcSEcCtD
Maraviroc—CCR5—Disease—MAPK3—kidney cancer	8.02e-05	0.000931	CbGpPWpGaD
Maraviroc—Myalgia—Doxorubicin—kidney cancer	7.93e-05	0.000175	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—kidney cancer	7.9e-05	0.000175	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.88e-05	0.000174	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—kidney cancer	7.85e-05	0.000911	CbGpPWpGaD
Maraviroc—Discomfort—Doxorubicin—kidney cancer	7.84e-05	0.000173	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—kidney cancer	7.8e-05	0.000905	CbGpPWpGaD
Maraviroc—Dizziness—Capecitabine—kidney cancer	7.8e-05	0.000172	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RAF1—kidney cancer	7.8e-05	0.000904	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RELA—kidney cancer	7.76e-05	0.0009	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB2—kidney cancer	7.71e-05	0.000895	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK1—kidney cancer	7.64e-05	0.000886	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTOR—kidney cancer	7.61e-05	0.000883	CbGpPWpGaD
Maraviroc—Oedema—Doxorubicin—kidney cancer	7.6e-05	0.000168	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—kidney cancer	7.59e-05	0.00088	CbGpPWpGaD
Maraviroc—Infection—Doxorubicin—kidney cancer	7.55e-05	0.000167	CcSEcCtD
Maraviroc—Vomiting—Capecitabine—kidney cancer	7.5e-05	0.000166	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	7.48e-05	0.000868	CbGpPWpGaD
Maraviroc—Shock—Doxorubicin—kidney cancer	7.48e-05	0.000165	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—kidney cancer	7.46e-05	0.000165	CcSEcCtD
Maraviroc—Rash—Capecitabine—kidney cancer	7.44e-05	0.000164	CcSEcCtD
Maraviroc—Dermatitis—Capecitabine—kidney cancer	7.43e-05	0.000164	CcSEcCtD
Maraviroc—Headache—Capecitabine—kidney cancer	7.39e-05	0.000163	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—kidney cancer	7.39e-05	0.000163	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—kidney cancer	7.25e-05	0.00016	CcSEcCtD
Maraviroc—CCR5—Disease—KRAS—kidney cancer	7.21e-05	0.000837	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—kidney cancer	7.14e-05	0.000829	CbGpPWpGaD
Maraviroc—Nausea—Capecitabine—kidney cancer	7.01e-05	0.000155	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL2—kidney cancer	6.99e-05	0.000811	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—kidney cancer	6.97e-05	0.000809	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.93e-05	0.000153	CcSEcCtD
Maraviroc—Insomnia—Doxorubicin—kidney cancer	6.88e-05	0.000152	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	6.88e-05	0.000798	CbGpPWpGaD
Maraviroc—Paraesthesia—Doxorubicin—kidney cancer	6.83e-05	0.000151	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCND1—kidney cancer	6.81e-05	0.00079	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JUN—kidney cancer	6.8e-05	0.000789	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—kidney cancer	6.75e-05	0.000783	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—kidney cancer	6.63e-05	0.000769	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	6.61e-05	0.000767	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—kidney cancer	6.61e-05	0.000146	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTEN—kidney cancer	6.58e-05	0.000763	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.56e-05	0.000145	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—kidney cancer	6.55e-05	0.000145	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	6.52e-05	0.000756	CbGpPWpGaD
Maraviroc—Constipation—Doxorubicin—kidney cancer	6.5e-05	0.000144	CcSEcCtD
Maraviroc—Pain—Doxorubicin—kidney cancer	6.5e-05	0.000144	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—kidney cancer	6.22e-05	0.000137	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—kidney cancer	6.01e-05	0.000133	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—kidney cancer	6.01e-05	0.000133	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—VEGFA—kidney cancer	5.94e-05	0.000689	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACY1—kidney cancer	5.81e-05	0.000675	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK3—kidney cancer	5.62e-05	0.000652	CbGpPWpGaD
Maraviroc—Hypersensitivity—Doxorubicin—kidney cancer	5.6e-05	0.000124	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—kidney cancer	5.47e-05	0.000634	CbGpPWpGaD
Maraviroc—Asthenia—Doxorubicin—kidney cancer	5.45e-05	0.00012	CcSEcCtD
Maraviroc—Pruritus—Doxorubicin—kidney cancer	5.38e-05	0.000119	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAPK1—kidney cancer	5.35e-05	0.00062	CbGpPWpGaD
Maraviroc—Diarrhoea—Doxorubicin—kidney cancer	5.2e-05	0.000115	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—kidney cancer	5.05e-05	0.000586	CbGpPWpGaD
Maraviroc—Dizziness—Doxorubicin—kidney cancer	5.03e-05	0.000111	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—PDHB—kidney cancer	4.94e-05	0.000574	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—POMC—kidney cancer	4.93e-05	0.000572	CbGpPWpGaD
Maraviroc—Vomiting—Doxorubicin—kidney cancer	4.83e-05	0.000107	CcSEcCtD
Maraviroc—Rash—Doxorubicin—kidney cancer	4.79e-05	0.000106	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—kidney cancer	4.79e-05	0.000106	CcSEcCtD
Maraviroc—Headache—Doxorubicin—kidney cancer	4.76e-05	0.000105	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—CCBL1—kidney cancer	4.65e-05	0.000539	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—kidney cancer	4.64e-05	0.000538	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—kidney cancer	4.52e-05	9.98e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TP53—kidney cancer	4.49e-05	0.000521	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.03e-05	0.000468	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPAT—kidney cancer	4.03e-05	0.000468	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APRT—kidney cancer	3.75e-05	0.000435	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FH—kidney cancer	3.75e-05	0.000435	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPC3—kidney cancer	3.52e-05	0.000409	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA2—kidney cancer	3.43e-05	0.000398	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALAD—kidney cancer	3.34e-05	0.000387	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.26e-05	0.000378	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.19e-05	0.00037	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PGK1—kidney cancer	3.05e-05	0.000354	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.05e-05	0.000354	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LDHB—kidney cancer	3e-05	0.000347	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA9—kidney cancer	2.6e-05	0.000301	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CRABP1—kidney cancer	2.21e-05	0.000256	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ITPR2—kidney cancer	2.05e-05	0.000238	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACHE—kidney cancer	1.87e-05	0.000217	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—kidney cancer	1.87e-05	0.000217	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SCARB1—kidney cancer	1.77e-05	0.000206	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS1—kidney cancer	1.75e-05	0.000204	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSMD7—kidney cancer	1.72e-05	0.0002	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BCHE—kidney cancer	1.63e-05	0.000189	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.61e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.56e-05	0.00018	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—kidney cancer	1.3e-05	0.000151	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—kidney cancer	1.23e-05	0.000142	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—kidney cancer	1.19e-05	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.13e-05	0.000131	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—POMC—kidney cancer	8.43e-06	9.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—kidney cancer	6.72e-06	7.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—kidney cancer	5.86e-06	6.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.14e-06	4.8e-05	CbGpPWpGaD
